clinical trial · NCT05297578
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
Pneumococcal Vaccines24-Valent Pneumococcal Conjugate VaccinePneumococcal 20-valent Conjugate Vaccine
brief summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
started
Jun 15, 2022
primary completion
Feb 15, 2023
completion
Feb 15, 2023
last updated
Oct 9, 2024
detailed description
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
official title
A Phase 2, Randomized, Observer-Blind, Dose-Finding, Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults 65 Years and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol